AVANOS MEDICAL INC (AVNS) Stock Fundamental Analysis

NYSE:AVNS • US05350V1061

13.64 USD
-1.59 (-10.44%)
At close: Feb 24, 2026
13.64 USD
0 (0%)
Pre-Market: 2/25/2026, 4:34:36 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

AVNS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AVNS get a neutral evaluation. Nothing too spectacular is happening here. AVNS has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • AVNS had positive earnings in the past year.
  • In the past year AVNS had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: AVNS reported negative net income in multiple years.
  • Of the past 5 years AVNS 4 years had a positive operating cash flow.
AVNS Yearly Net Income VS EBIT VS OCF VS FCFAVNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -43.92%, AVNS is doing worse than 64.32% of the companies in the same industry.
  • AVNS has a Return On Equity (-60.27%) which is comparable to the rest of the industry.
  • Looking at the Return On Invested Capital, with a value of 2.68%, AVNS is in the better half of the industry, outperforming 68.65% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for AVNS is significantly below the industry average of 8.75%.
  • The last Return On Invested Capital (2.68%) for AVNS is above the 3 year average (2.58%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -43.92%
ROE -60.27%
ROIC 2.68%
ROA(3y)-11.6%
ROA(5y)-7.22%
ROE(3y)-16.14%
ROE(5y)-10.03%
ROIC(3y)2.58%
ROIC(5y)N/A
AVNS Yearly ROA, ROE, ROICAVNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

  • AVNS's Operating Margin of 4.46% is fine compared to the rest of the industry. AVNS outperforms 68.65% of its industry peers.
  • In the last couple of years the Operating Margin of AVNS has grown nicely.
  • Looking at the Gross Margin, with a value of 52.28%, AVNS is in line with its industry, outperforming 48.11% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AVNS has remained more or less at the same level.
Industry RankSector Rank
OM 4.46%
PM (TTM) N/A
GM 52.28%
OM growth 3Y42.57%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.25%
GM growth 5Y-0.78%
AVNS Yearly Profit, Operating, Gross MarginsAVNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AVNS is destroying value.
  • There is no outstanding debt for AVNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVNS Yearly Shares OutstandingAVNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AVNS Yearly Total Debt VS Total AssetsAVNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • AVNS has an Altman-Z score of 1.27. This is a bad value and indicates that AVNS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of AVNS (1.27) is comparable to the rest of the industry.
  • The Debt to FCF ratio of AVNS is 1.38, which is an excellent value as it means it would take AVNS, only 1.38 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 1.38, AVNS belongs to the best of the industry, outperforming 89.19% of the companies in the same industry.
  • A Debt/Equity ratio of 0.12 indicates that AVNS is not too dependend on debt financing.
  • AVNS has a Debt to Equity ratio of 0.12. This is in the better half of the industry: AVNS outperforms 63.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 1.38
Altman-Z 1.27
ROIC/WACC0.27
WACC10%
AVNS Yearly LT Debt VS Equity VS FCFAVNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.38 indicates that AVNS has no problem at all paying its short term obligations.
  • AVNS has a Current ratio (2.38) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.36 indicates that AVNS should not have too much problems paying its short term obligations.
  • AVNS has a Quick ratio of 1.36. This is in the lower half of the industry: AVNS underperforms 61.62% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 1.36
AVNS Yearly Current Assets VS Current LiabilitesAVNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • AVNS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.40%.
  • AVNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.80% yearly.
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.72%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.57% on average over the next years. This is a very strong growth
  • AVNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.19% yearly.
EPS Next Y3.09%
EPS Next 2Y24.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVNS Yearly Revenue VS EstimatesAVNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
AVNS Yearly EPS VS EstimatesAVNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 14.51, which indicates a correct valuation of AVNS.
  • Compared to the rest of the industry, the Price/Earnings ratio of AVNS indicates a rather cheap valuation: AVNS is cheaper than 89.73% of the companies listed in the same industry.
  • AVNS is valuated rather cheaply when we compare the Price/Earnings ratio to 26.98, which is the current average of the S&P500 Index.
  • AVNS is valuated correctly with a Price/Forward Earnings ratio of 14.08.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AVNS indicates a rather cheap valuation: AVNS is cheaper than 89.73% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.01. AVNS is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 14.51
Fwd PE 14.08
AVNS Price Earnings VS Forward Price EarningsAVNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AVNS is valued cheaply inside the industry as 92.97% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AVNS indicates a rather cheap valuation: AVNS is cheaper than 98.92% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.48
EV/EBITDA 9.28
AVNS Per share dataAVNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AVNS does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as AVNS's earnings are expected to grow with 24.57% in the coming years.
PEG (NY)4.7
PEG (5Y)3.82
EPS Next 2Y24.57%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AVNS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVANOS MEDICAL INC

NYSE:AVNS (2/24/2026, 8:09:44 PM)

Premarket: 13.64 0 (0%)

13.64

-1.59 (-10.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners96.89%
Inst Owner Change27.63%
Ins Owners2.95%
Ins Owner Change-0.82%
Market Cap633.17M
Revenue(TTM)N/A
Net Income(TTM)-468.90M
Analysts43.33
Price TargetN/A
Short Float %7.65%
Short Ratio6.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.42%
Min EPS beat(2)11.11%
Max EPS beat(2)79.74%
EPS beat(4)4
Avg EPS beat(4)33.85%
Min EPS beat(4)2.94%
Max EPS beat(4)79.74%
EPS beat(8)4
Avg EPS beat(8)13.31%
EPS beat(12)7
Avg EPS beat(12)15.99%
EPS beat(16)10
Avg EPS beat(16)13.31%
Revenue beat(2)2
Avg Revenue beat(2)4.82%
Min Revenue beat(2)3.67%
Max Revenue beat(2)5.97%
Revenue beat(4)3
Avg Revenue beat(4)2.62%
Min Revenue beat(4)-0.66%
Max Revenue beat(4)5.97%
Revenue beat(8)3
Avg Revenue beat(8)0.51%
Revenue beat(12)3
Avg Revenue beat(12)-1.11%
Revenue beat(16)3
Avg Revenue beat(16)-4.54%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)13.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.81%
Valuation
Industry RankSector Rank
PE 14.51
Fwd PE 14.08
P/S 0.9
P/FCF 8.48
P/OCF 6.08
P/B 0.81
P/tB 2.42
EV/EBITDA 9.28
EPS(TTM)0.94
EY6.89%
EPS(NY)0.97
Fwd EY7.1%
FCF(TTM)1.61
FCFY11.8%
OCF(TTM)2.24
OCFY16.46%
SpS15.08
BVpS16.76
TBVpS5.64
PEG (NY)4.7
PEG (5Y)3.82
Graham Number18.83
Profitability
Industry RankSector Rank
ROA -43.92%
ROE -60.27%
ROCE 3.39%
ROIC 2.68%
ROICexc 2.9%
ROICexgc 7.4%
OM 4.46%
PM (TTM) N/A
GM 52.28%
FCFM 10.67%
ROA(3y)-11.6%
ROA(5y)-7.22%
ROE(3y)-16.14%
ROE(5y)-10.03%
ROIC(3y)2.58%
ROIC(5y)N/A
ROICexc(3y)2.84%
ROICexc(5y)N/A
ROICexgc(3y)9.32%
ROICexgc(5y)N/A
ROCE(3y)3.26%
ROCE(5y)N/A
ROICexgc growth 3Y51.11%
ROICexgc growth 5YN/A
ROICexc growth 3Y59.93%
ROICexc growth 5YN/A
OM growth 3Y42.57%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.25%
GM growth 5Y-0.78%
F-Score6
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 1.38
Debt/EBITDA 1.3
Cap/Depr 72.84%
Cap/Sales 4.21%
Interest Coverage 250
Cash Conversion 145.33%
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 1.36
Altman-Z 1.27
F-Score6
WACC10%
ROIC/WACC0.27
Cap/Depr(3y)39.4%
Cap/Depr(5y)44.02%
Cap/Sales(3y)2.53%
Cap/Sales(5y)2.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
EPS Next Y3.09%
EPS Next 2Y24.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.72%
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.96%
EBIT growth 3Y38.85%
EBIT growth 5YN/A
EBIT Next Year51.47%
EBIT Next 3Y22.03%
EBIT Next 5YN/A
FCF growth 1Y104.1%
FCF growth 3Y7.73%
FCF growth 5YN/A
OCF growth 1Y95.13%
OCF growth 3Y4.87%
OCF growth 5YN/A

AVANOS MEDICAL INC / AVNS FAQ

Can you provide the ChartMill fundamental rating for AVANOS MEDICAL INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVNS.


What is the valuation status for AVNS stock?

ChartMill assigns a valuation rating of 6 / 10 to AVANOS MEDICAL INC (AVNS). This can be considered as Fairly Valued.


Can you provide the profitability details for AVANOS MEDICAL INC?

AVANOS MEDICAL INC (AVNS) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for AVNS stock?

The Earnings per Share (EPS) of AVANOS MEDICAL INC (AVNS) is expected to grow by 3.09% in the next year.